Ms. Sullivan is a seasoned life sciences professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Ms. Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer.
Prior to her time with TABA, Ms. Sullivan was chief strategy office for Euronext-listed Kiadis Pharma where she was responsible for all aspects of fundraising and capital formation strategy, repositioning the company after a clinical failure, and played a critical role in the company’s sale to Sanofi.
Prior to Kiadis, Ms. Sullivan served Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International.
Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her master's of business administration from Bentley University.
What is Amy Sullivan's net worth?
The estimated net worth of Amy Sullivan is at least $4.06 thousand as of December 23rd, 2024. Ms. Sullivan owns 84,632 shares of IO Biotech stock worth more than $4,062 as of October 10th. This net worth estimate does not reflect any other investments that Ms. Sullivan may own. Learn More about Amy Sullivan's net worth.
How do I contact Amy Sullivan?
Has Amy Sullivan been buying or selling shares of IO Biotech?
Amy Sullivan has not been actively trading shares of IO Biotech within the last three months. Most recently, on Monday, December 23rd, Amy Sullivan bought 10,250 shares of IO Biotech stock. The stock was acquired at an average cost of $0.83 per share, with a total value of $8,507.50. Following the completion of the transaction, the chief financial officer now directly owns 84,632 shares of the company's stock, valued at $70,244.56. Learn More on Amy Sullivan's trading history.
Who are IO Biotech's active insiders?
